- Home
- INO vs VRCA Comparison
INO vs VRCA Comparison
Compare INO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- VRCA
- Stock Information
- Founded
- INO 1979
- VRCA 2013
- Country
- INO United States
- VRCA United States
- Employees
- INO N/A
- VRCA N/A
- Industry
- INO Medical/Dental Instruments
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- VRCA Health Care
- Exchange
- INO Nasdaq
- VRCA Nasdaq
- Market Cap
- INO 69.3M
- VRCA 80.7M
- IPO Year
- INO 1998
- VRCA 2018
- Fundamental
- Price
- INO $1.43
- VRCA $6.24
- Analyst Decision
- INO Buy
- VRCA Hold
- Analyst Count
- INO 5
- VRCA 5
- Target Price
- INO $8.80
- VRCA $6.00
- AVG Volume (30 Days)
- INO 3.4M
- VRCA 75.1K
- Earning Date
- INO 08-07-2025
- VRCA 08-13-2025
- Dividend Yield
- INO N/A
- VRCA N/A
- EPS Growth
- INO N/A
- VRCA N/A
- EPS
- INO N/A
- VRCA N/A
- Revenue
- INO $283,099.00
- VRCA $7,179,000.00
- Revenue This Year
- INO N/A
- VRCA $165.25
- Revenue Next Year
- INO $20,588.06
- VRCA $80.06
- P/E Ratio
- INO N/A
- VRCA N/A
- Revenue Growth
- INO N/A
- VRCA N/A
- 52 Week Low
- INO $1.30
- VRCA $3.82
- 52 Week High
- INO $11.44
- VRCA $73.30
- Technical
- Relative Strength Index (RSI)
- INO 40.29
- VRCA 40.92
- Support Level
- INO $1.46
- VRCA $5.86
- Resistance Level
- INO $1.56
- VRCA $7.13
- Average True Range (ATR)
- INO 0.08
- VRCA 0.92
- MACD
- INO 0.02
- VRCA -0.26
- Stochastic Oscillator
- INO 43.33
- VRCA 10.44
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.